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The 2.07 A ˚ resolution X-ray crystal structure of a soluble
Rieske-type ferredoxin from Mus musculus encoded by the
gene Mm.266515 is reported. Although they are present as
covalent domains in eukaryotic membrane oxidase complexes,
soluble Rieske-type ferredoxins have not previously been
observed in eukaryotes. The overall structure of the mouse
Rieske-type ferredoxin is typical of this class of iron–sulfur
proteins and consists of a larger partial -barrel domain and a
smaller domain containing Cys57, His59, Cys80 and His83 that
binds the [2Fe–2S] cluster. The S atoms of the cluster are
hydrogen-bonded by six backbone amide N atoms in a pattern
typical of membrane-bound high-potential eukaryotic respira-
tory Rieske ferredoxins. However, phylogenetic analysis
suggested that the mouse Rieske-type ferredoxin was more
closely related to bacterial Rieske-type ferredoxins. Corre-
spondingly, the structure revealed an extended loop most
similar to that seen in Rieske-type ferredoxin subunits of
bacterial aromatic dioxygenases, including the positioning of
an aromatic side chain (Tyr85) between this loop and the
[2Fe–2S] cluster. The mouse Rieske-type ferredoxin was
shown to be capable of accepting electrons from both
eukaryotic and prokaryotic oxidoreductases, although it was
unable to serve as an electron donor for a bacterial mono-
oxygenase complex. The human homolog of mouse Rieske-
type ferredoxin was also cloned and puriﬁed. It behaved
identically to mouse Rieske-type ferredoxin in all biochemical
characterizations but did not crystallize. Based on its high
sequence identity,the structure ofthe humanhomolog is likely
to be modeled well by the mouse Rieske-type ferredoxin
structure.
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1. Introduction
Rieske ferredoxins were originally identiﬁed by an unusual
EPR signal in beef heart mitochondria preparations (Rieske,
1968). They are now well characterized as containing two Fe
atoms and two bridging S atoms arranged in a tetrahedral
rhombus, with one iron coordinated by the ND1 atoms of two
histidine residues and the other iron coordinated by the SG
atoms of two cysteine residues. In the oxidized [2Fe–2S]
cluster both Fe atoms carry charges of 3+, while in the reduced
form the iron coordinated by two histidines assumes the 2+
state (Fee et al., 1984; Iwata et al., 1996).
Although the fold of the various Rieske and Rieske-type
ferredoxins is well conserved, their sequence identity is low.
Only the four residues coordinating the cluster are absolutelyconserved and these are arranged in a CXHa ndC XXH metal-
binding motif separated by a variable sequence of typically not
less than 15 residues (Schmidt & Shaw, 2001). Other amino-
acid positions in these ubiquitously distributed proteins have
diverged extensively.
Rieske ferredoxins are involved in a wide variety of bio-
logical functions. They typically act as electron carriers
between different redox partners. Membrane-bound Rieske
ferredoxins are found as covalent domains in the cytochrome
bc1, b6f and bc respiratory complexes in mitochondria, chloro-
plasts and bacterial cell walls (Trumpower & Gennis, 1994), as
well as in the respiratory chains of archaeal organisms
(Schafer et al., 1996). In bacteria, Rieske-type ferredoxins are
found in tightly bound subunits of arsenite oxidase (Ellis et al.,
2001), nitrite reductases (Lledo et al., 2004) and the oxygenase
components of various aromatic ring-hydroxylating mono-
oxygenases and dioxygenases (Ferraro et al., 2005). Rieske-
type ferredoxins also participate as soluble electron carriers
in some bacterial monooxygenases and dioxygenases. In
mammals, proteins previously observed to contain Rieske
[2Fe–2S] clusters include CMP-N-acetylneuraminic acid
hydroxylase (Schlenzka et al., 1996) and a protein homologous
to apoptosis-inducing factor, the Rieske domain of which has
been shown to induce apoptosis in human cell cultures (Xie et
al., 2005).
As part of our application of structural genomics methods
to eukaryotic proteins, we investigated the proteins encoded
by the mouse gene Mm.266515 and its human homolog
Hs.BC024023. Here, we describe the cloning and puriﬁcation
of previously uncharacterized soluble Rieske-type ferredoxins
from Mus musculus (MRF) and Homo sapiens (HRF) of
unknown function and the determination of the X-ray struc-
ture of MRF to 2.07 A ˚ . The function of these proteins is
presently unknown. However, the crystal structure exhibits a
high degree of similarity to the structures of the bacterial
Rieske ferredoxin domains of various aromatic oxygenase
complexes (Kauppi et al., 1998; Colbert et al., 2000; Moe et al.,
2006; Nam et al., 2005). In addition, we demonstrate that MRF
and HRF can be reduced chemically by dithionite and bio-
logically by both prokaryotic and eukaryotic oxidoreductases.
2. Methods
2.1. Materials
Unless otherwise noted, all materials were purchased from
Sigma–Aldrich (St Louis, Missouri, USA). The cDNA
containing the Mm.266515 gene was purchased from Open
Biosystems (Huntsville, Alabama, USA).
2.2. Cloning and expression
The gene Mm.266515 encoding MRF or Hs.BC024023
encoding HRF was cloned into expression plasmid pVP16 to
allow production of the protein as an N-terminal fusion to
His8-maltose-binding protein (Thao et al., 2004). Escherichia
coli BL21 transformed with the plasmid containing the target
gene was grown in 4 l Erlenmeyer ﬂasks containing 1 l Luria-–
Bertani medium modiﬁed by the addition of 50 mM phosphate
buffer pH 6.7 containing 50 mM NH4Cl, 5 mM Na2SO4 and
100 mgm l
1 ampicillin. Expression was induced by the addi-
tion of IPTG (10 mM ﬁnal concentration), l-cysteine (1 mM
ﬁnal concentration), Fe(NH4)2(SO4)2 (100 mM ﬁnal concen-
tration), 1 g l
1 casamino acids and 0.4%(w/v) glycerol when
the shaken ﬂask culture reached an OD600 of 0.4. After
induction, the culture was grown overnight (14 h) at 303 K.
2.3. Protein purification
All protein-puriﬁcation steps were performed at 277 K. 2 ml
buffer A (25 mM MOPS pH 7.4 containing 200 mM NaCl and
1m M dithiothreitol) was added per gram of frozen cell paste.
The resuspended cells were amended with 1 mg each of
RNAse, DNAse and lysozyme and lysed by sonication. After
sonication, the lysed cells were further diluted with 2 ml buffer
A per gram of cell paste and centrifuged at 40 000g for 1 h.
The supernatant was loaded onto a 45 ml amylose column
equilibrated in buffer A. The column was washed with ﬁve
column volumes of buffer A. The bound protein was batch-
eluted with one column volume of buffer A containing 10 mM
maltose. Tobacco etch virus (TEV) protease was added to the
eluted protein to a concentration of 1 g per 100 g of total
protein and allowed to react overnight. The net result of
fusion to MBP followed by cleavage by TEV protease was the
replacement of the N-terminal methionine by serine. The
solution was then concentrated to 4 ml and loaded onto a
16/60 Sephadex S-100 gel-ﬁltration column (GE Healthcare,
Piscataway, New Jersey, USA) equilibrated in buffer B
[25 mM MOPS pH 7.2 containing 100 mM NaCl, 7%(w/v)
glycerol, 5 mM maltose and 1 mM dithiothreitol]. Fractions
containing MRF were pooled based on the presence of an
optical absorption spectrum typical of an iron–sulfur protein,
concentrated and dialyzed into crystallization buffer (10 mM
MOPS pH 7.0 containing 25 mM NaCl). The ﬁnal protein
concentration was measured by Bradford assay.
2.4. Crystallization and data collection
The puriﬁed MRF was crystallized by hanging-drop vapor
diffusion at 293 K with a reservoir solution consisting of
120 mM trisodium citrate, 100 mM MES pH 6.0–6.5 and 22–
25% PEG MME 5000. The drops contained 2 ml reservoir
solution and 2 ml protein solution, resulting in the initial drop
having a protein concentration of 7.5 mg ml
1. The resulting
crystals were deep red octahedrons roughly 75  75  100 mm
in size. After soaking for approximately 3 min in cyroprotec-
tant consisting of the reservoir solution plus 15% ethylene
glycol, the crystals were ﬂash-frozen in liquid N2. In addition
to the native crystals, mercury derivatives were prepared by
soaking the crystals overnight in solutions of mother liquor
with 2 mM thimerosal added. Diffraction data were collected
from a single mercury-derivatized crystal on the Southeast
Regional Collaborative Access Team beamline 22-ID at the
Advanced Photon Source at a wavelength of 1.0 A ˚ to a
nominal resolution of 1.7 A ˚ . An additional data set was
collected on a crystal of the native protein to a resolution of
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borative Access Team beamline 23-ID-D using a wavelength
of 0.964 A ˚ . Both data sets were indexed and scaled using
HKL-2000 (Otwinowski & Minor, 1997).
2.5. Phasing and structure solution
The programs HySS from the Phenix suite (Adams et al.,
2002) and SHELXD (Sheldrick, 2008) were used to locate
four Hg atoms in the asymmetric unit of the thimerosal-
derivatized crystal. The structure was phased using the
program autoSHARP (Vonrhein et al., 2006) and an initial
model was built using ARP/wARP (Cohen et al., 2004). Model
building and reﬁnement were continued using Coot (Emsley &
Cowtan, 2004) and REFMAC (Murshudov et al., 1997; Winn et
al., 2001) until 137 residues had been located and R and Rfree
were 19.8% and 24.1%, respectively. The resulting model was
then used to obtain phases for the 2.07 A ˚ native data set by
molecular replacement in MOLREP (Vagin & Teplyakov,
1997). After additional model building and TLS reﬁnement
using TLS groups determined by the program TLSMD
(Painter & Merritt, 2006), the geometry of the ﬁnal model was
assessed using MOLPROBITY (Davis et al., 2007).
2.6. Reductive titrations
For studies of sodium dithionite reduction, 90 mM MRF was
made anaerobic in a sealed quartz cuvette by repeated cycles
of vacuum/argon. Reductant (a concentrated solution of
sodium dithionite quantiﬁed by reductive titration of potas-
sium ferricyanide) was added in 1 ml aliquots using a gas-tight
syringe. The optical spectrum of MRF was monitored using a
Hewlett Packard 8453 diode array spectrophotometer.
Reduction rates were measured similarly, except that T4moF,
a prokaryotic oxidoreductase, was included in the anaerobic
cuvette at 4 nM. Anaerobic NADH was then added to a ﬁnal
concentration of 1 mM. The rate was calculated from the
initial linear decrease in absorbance at 460 nm.
2.7. Other methods
The total iron content was measured by the tripyridyl-S-
triazine assay (Fischer & Price, 1964). Rieske ferredoxin
sequences were aligned and a phylogenetic tree was
constructed using MegAlign (Clewley & Arnold, 1997). The
amino-acid sequences of multisubunit enzymes were trimmed
to the Rieske domain. The resulting sequence-based align-
ment was then edited based on the backbone alignment of the
crystal structures using the align routine in PyMOL (DeLano
Scientiﬁc LLC, San Carlos, California, USA). Electrostatic
surface calculations were performed using the APBS Tools
plugin for PyMOL (Baker et al., 2001).
3. Results and discussion
3.1. Phylogenetic analysis
Fig. 1 shows a phylogenetic tree of some Rieske proteins
and Rieske-type ferredoxins from a variety of species. T4moC
and TbuB are soluble Rieske-type ferredoxins that function
as electron carriers to bacterial multicomponent mono-
oxygenases (Leahy et al., 2003). BphF and CarAc are also
soluble bacterial Rieske-type ferredoxins, but they transfer
electrons to Rieske nonheme iron oxygenases (ROs; Colbert
et al., 2000; Nam et al., 2005). Naphthalene dioxygenase
(NDO) is an RO, the Rieske domain of which has been used in
the sequence alignment (Kauppi et al., 1998). The Thermus
thermophilus (Tt) and spinach Rieske proteins are membrane-
tethered and function in chemiosmotic respiratory complexes
(Hunsicker-Wang et al., 2003; Carrell et al., 1997). The enzyme
arsenite oxidase (AO) from Alcaligenes faecalis is a molyb-
denum/iron protein involved in the detoxiﬁcation of arsenic
and contains a 133-amino-acid Rieske subunit (Ellis et al.,
2001).
Homologs to MRF are present in the genome sequences of
other vertebrate animals and the human homolog (HRF) is
included in the phylogenetic tree. Interestingly, this protein
clade is more closely related to the prokaryotic soluble
Rieske-type ferredoxins than the membrane-bound Rieske
proteins found in the respiratory complexes of eukaryotes.
3.2. Expression and purification
Overnight induction of cells transformed with the MRF
expression plasmid yielded 6 g per litre of wet cell paste.
Overnight induction with 10 mM IPTG resulted in an expres-
sion level of between 10% and 20% of the total cellular
protein. Higher expression levels could be achieved with
higher IPTG concentrations (>40% of the total protein), but
this always resulted in lower [2Fe–2S] cluster incorporation.
The expressed fusion protein was puriﬁed to >95% purity by a
two-step puriﬁcation consisting of an amylose resin afﬁnity-
chromatography step and a gel-ﬁltration step. The MRF, with
a calculated molecular weight of 18 kDa, was not separated
from the His8-MBP fragment (46 kDa) using gel-ﬁltration
chromatography unless maltose was included in the column
buffer. This is likely to be the consequence of a conforma-
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Figure 1
Phylogenetic tree constructed based on a structure-edited alignment of
Rieske protein sequences.tional change of MBP upon binding maltose (Sharff et al.,
1992) which causes an altered elution pattern.
The puriﬁed MRF had a distinctive red–brown color and
the optical absorbance spectrum showed peaks at 330 and
460 nm with molar absorptivity constants of 6000 and
11 600 M
1 cm
1, respectively, and a shoulder at 570 nm. This
spectrum is typical of a Rieske ferredoxin (Fig. 2). The iron
content of the puriﬁed protein was only 45% of that expected,
indicating incomplete [2Fe–2S] cofactor incorporation during
expression in the exogenous host or partial loss during the
puriﬁcation procedure. Expression and puriﬁcation of HRF
following the same protocol resulted in similar purity and
[2Fe–2S] cofactor incorporation; however, HRF had an
increased tendency to form high-molecular-weight aggregates
as evidenced by a peak containing HRF eluting in the void
volume of the gel-ﬁltration column. This possibly contributed
to the difﬁculty in crystallizing HRF. The optical spectra of the
two proteins are identical and only the spectrum of MRF is
shown in Fig. 2.
3.3. Structure determination
Single crystals were grown of the native form of MRF.
Attempts to obtain single large crystals of HRF were unsuc-
cessful and yielded only rosettes and microcrystals. After
attempts to locate two distinct Fe sites in data sets collected
from native crystals at the Fe absorption edge failed, crystals
derivatized with thimerosal were obtained. Table 1 shows the
data-collection and reﬁnement statistics for MRF. The struc-
ture of the thimerosal derivative of MRF was solved to 1.7 A ˚
resolution using SAD and a model containing 132 of the
protein’s 157 residues and four ethylmercury molecules was
built into the electron density, while the ﬁrst 12 N-terminal
residues, three residues from an extended solvent-exposed
loop and the last ten C-terminal residues were missing. An
additional 2.07 A ˚ resolution data set was obtained from a
native crystal. Although the phasing data set had a higher
resolution, the electron density in the regions of the ethyl-
mercury sites was poor and a signiﬁcant change in the unit-cell
parameters (Table 1) with respect to the native crystals
suggested that the binding of the Hg atoms changed the
structure of the protein. For this reason, the structure obtained
for the phasing data set was used for molecular replacement
against the 2.07 A ˚ native data. Of the total of 157 residues in
the native protein, 129 were ﬁtted into electron density. The
missing residues were the same residues that were absent from
the mercury-derivative structure, along with one extra
N-terminal residue and two residues of the extended loop,
which was displaced signiﬁcantly from its position in the
derivatized structure. At this stage, it was apparent that
extending the C-terminus by another seven residues could ﬁll
a cylinder of strong positive density clearly corresponding to
protein backbone near the active site. Because the side chains
in this region were very poorly resolved, there were multiple
possible conformations of the C-terminus that could satisfy
the electron density equally well. This density was also absent
in the mercury-bound structure; in fact, the positioning of the
symmetry-related protein in the adjacent asymmetric unit
would preclude the placement of any residues in this location.
Although these C-terminal residues were included in the
deposited structure, their positioning should be considered
speculative and likely to be an artefact of crystal packing. The
ﬁnal model contained 136 protein residues, 45 water mole-
cules, a [2Fe–2S] iron–sulfur cluster and one molecule of
ethylene glycol.
3.4. Overall fold
MRF exhibits the two-domain fold common to all Rieske
proteins. The larger domain consists of a partial -barrel made
up of six antiparallel strands commonly labelled 1, 2, 3, 4,
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Figure 2
Electronic absorption spectra of oxidized (black line) and reduced (red
line) MRF. The change in absorbance at 460 nm was monitored for
reduction studies.
Table 1
Data-collection and reﬁnement statistics.
A summary of crystal and data-collection statistics for the thimerosal-
derivatized crystals and reﬁnement statistics for the corresponding models.
Values in parentheses are for the highest resolution shell (1.69–1.73 A ˚ for the
derivative data set and 2.07–2.14 A ˚ for the native data set).
Thimerosal derivative Native
Data collection
Space group P43212 P43212
Unit-cell parameters (A ˚ ) a = 52.67, c = 108.01 a = 52.41, c = 108.81
Wavelength (A ˚ ) 1.00 0.964
Resolution (A ˚ ) 1.69 2.07
Unique reﬂections 16626 9282
Completeness (%) 98.7 (90.2) 99.4 (95.5)
I/(I) 12.9 (1.33) 18.4 (1.84)
Rmerge (%) 17.6 5.7
Reﬁnement
No. of TLS groups† 5 4
R factor (%) 19.8 (25.7) 19.9 (29.5)
Rfree (%) 24.1 (37.6) 22.8 (37.8)
Bond r.m.s.d. (A ˚ ) 0.017 0.019
Angle r.m.s.d. () 1.820 1.848
PDB code — 3d89
† For the thimerosal-deriviatized structure, the TLS groups covered residues 13–36, 37–
55, 56–93, 94–119 and 120–148. In the native structure, the four TLS groups covered
residues 14–18, 19–35, 36–133 and 134–154.9 and 10 (Fig. 3). Despite the low sequence identity, the
backbone of this domain is virtually identical to those of the
large domains found in the previously solved structures of
BphF (Colbert et al., 2000), T4moC (Moe et al., 2006) and
CarAc (Nam et al., 2005), the ferredoxin components of
biphenyl dioxygenase, toluene 4-monooxygenase and carba-
zole 1,9a-dioxygenase, respectively (Fig. 5a). The smaller
cluster-binding domain is more divergent among the three
proteins. This domain typically consists of a four-stranded
antiparallel -sheet (strands 5, 6, 7 and 8). The [2Fe–2S]
cluster is located near the surface of the protein between the
four-stranded sheet and the large domain and is primarily
made up of the random coil before the 5 strand and the loop
connecting 6 and 7. MRF differs from BphFand T4moC in
the length of the 5 and 6 -strands of its cluster-binding
domain, which are longer and have a more pronounced right-
handed twist than the bacterial ferredoxins, and in the loop
following the 8 -strand, where MRF forms a two-strand
-sheet with the X strand ﬁve residues in length ending in
disordered random coil over 14 A ˚ away from the bulk of
protein. Large loops between the 8 and 9 strands are
typically found in the Rieske domains of trimeric aromatic
ring dioxygenases, where the side of the loop facing the active
site forms part of the interface with the adjacent subunit.
3.5. Electrostatic surface
Fig. 4 shows electrostatic surfaces of MRF (Fig. 4a) and
T4moC (Fig. 4b). Arg65 of T4moC has been demonstrated to
be an important determinant of binding speciﬁcity between
T4moC and its electron donor, the oxidoreductase T4moF
(Elsen et al., manuscript in preparation). Arg65 of T4moC is
the slightly basic patch in the center of the molecule. MRF has
been aligned and oriented similarly. A large acidic patch is
visible directly beneath Arg65 in the T4moC structure. In
contrast, MRF has a near-equal mixture of basic and acidic
surface area and has a net charge of 2.6 at pH 7.5 compared
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Figure 4
Electrostatic surfaces of MRF and T4moC. The structures of MRF (a)
and T4moC (b) were aligned in PyMOL and electrostatic surfaces were
computed using the APBS Tools plugin (Baker et al., 2001) for a range
from 10kT/e to 10kT/e, with basic areas in blue and acidic areas in red.
Both proteins are shown in the same orientation, with the cluster-binding
domain on top and the proline loop facing away from the viewer.
Figure 3
Ribbon representation of mouse soluble Rieske ferredoxin. The large
domain is shown in blue and the cluster-binding domain in green. The
iron–sulfur cluster is shown as spheres, with the S atoms colored yellow
and the Fe atoms gray. The dashed line indicates the approximate
location of ﬁve disordered residues in the 8–X loop.with 14.5 for T4moC. The extended proline loop of MRF is
visible at the top of the structure. The surface of the loop
facing the [2Fe–2S] cluster has signiﬁcant positive charge and
protrudes well above the histidine ligands. In contrast, the
area surrounding the [2Fe–2S] cluster of T4moC is negatively
charged and the histidine ligands are unobstructed by the
proline loop. The large differences in surface charge and
morphology between MRF and T4moC offer a physical basis
for the low second-order rate constant for reduction of MRF
by T4moF (see below). These factors, in addition to the
expected difference in reduction potential between T4moC
and MRF, may also explain the inability of MRF to transfer
electrons to T4moH.
3.6. Iron–sulfur cluster-binding site
The architectures of the iron–sulfur cluster-binding sites in
previously solved structures of Rieske-type proteins have
been classiﬁed into two different types. Both types have two
loops containing the CXH and CXXH motifs, which also
provide many of the hydrogen bonds to the S atoms of the
cluster and the ligating cysteine residues. In the ﬁrst type,
representing the majority of Rieske and Rieske-type proteins,
a third loop containing a highly conserved proline residue
interacts with the S1 atom of the iron–sulfur cluster, protecting
it from the solvent. In the second type, which includes the
ferredoxin components of monooxygenase complexes (Moe et
al., 2006) and the oxygenase components of dioxygenase
complexes (Dong et al., 2005; Friemann et al., 2005; Furusawa
et al., 2004; Kauppi et al., 1998; Nojiri et al., 2005) and some
monooxygenases (Martins et al., 2005), this third loop is highly
variable in length and sequence and is displaced away from
the active site by the side chain of an aromatic residue located
two residues after the CXXH motif. The aromatic side chain,
which is frequently a tryptophan, takes the place of the
conserved proline and sits with one face adjacent to the S1
atom of the iron–sulfur cluster. The active site of MRF falls
into this latter category and provides the ﬁrst example of a
tyrosine residue taking the place of the conserved proline. The
tyrosine ring lies roughly perpendicular to the plane of the
iron–sulfur cluster, with the ring atoms located 3.6–4.9 A ˚ away
from the S1 atom.
Fig. 5(b) shows the structure of MRF near the [2Fe–2S]
cluster. The cluster is coordinated by residues His59 and His83
at the Fe1 atom and residues Cys57 and Cys80 at the Fe2 atom.
The geometry of the cluster is consistent within error with
previous high-resolution structures of
Rieske proteins (Hunsicker-Wang et al.,
2003; Bonisch et al., 2002). Based on the
criteria for identifying a hydrogen bond
used by Hunsicker-Wang et al. (2003), i.e. a
distance between the electron donor and
acceptor of not more than 3.8 A ˚ and an
angle formed by the donor, acceptor and
heavy atom of not less than 120, the four S
atoms participate in a total of six hydrogen
bonds with the backbone amide H atoms of
the surrounding residues (Fig. 5b). Both of
the cluster S atoms are hydrogen bonded by
two residues: S2 by Ser60 and Gly62, and S1
by His83 and Tyr85. The S atoms of the
ligating cysteines each form one hydrogen
bond; speciﬁcally, His59 hydrogen bonds to
the S atom of Cys57 and Trp82 to the S atom
of Cys80. The arrangement of bonds is
roughly symmetric about the cluster’s
twofold rotational axis.
The [2Fe–2S] centers of Rieske proteins
exhibit a broad spectrum of redox potentials
ranging between 167 and +490 mV
(Schmidt & Shaw, 2001). Hunsicker-Wang
and coworkers have shown a strong corre-
lation between the number and nature of
hydrogen bonds to the S atoms of the cluster
and the coordinating cysteine residues, with
stronger more numerous bonds stabilizing
the reduced state and thus increasing the
redox potential. Also, the presence of an
aromatic residue located two residues after
the CXXH motif has been proposed to
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Figure 5
Comparison of Rieske ferredoxin folds and the MRF active site. (a) Stereo image of the
alignment of MRF (cyan), BphF (PDB code 1fqt, gray), T4moC (PDB code 1vm9, green) and
CarAc (PDB code 1vck, red). The positioning of the space-ﬁlling representation of the iron–
sulfur cluster corresponds to its location in the MRF structure. (b) Stereo image of the MRF
active site and residues participating in hydrogen bonding to the atoms of the iron–sulfur
cluster and the cysteine S atoms, which are represented as spheres.lower the redox potential by placing the electron density from
the aromatic side chain adjacent to the [2Fe–2S] center (Elsen
et al., 2007). MRF’s total of six hydrogen bonds to the cluster
and its coordinating cysteines is higher than that observed for
previously solved structures of the ferredoxin components of
bacterial ROs. For example, T4moC, BphF and CarAc have
ﬁve, three and two active-site hydrogen bonds and redox
potentials of 173, 157 and 169 mV, respectively (Elsen et
al., 2007). However, the presence of Tyr85 adjacent to the
[2Fe–2S] center of MRF may partially offset the effect of the
additional hydrogen bonds. MRF is predicted to have a redox
potential that is slightly more positive than those of the
soluble Rieske-type ferredoxins mentioned.
3.7. Chemical and enzymatic reduction of MRF
MRF was readily reduced by sodium dithionite (Fig. 2). It
was also found that MRF could be enzymatically reduced by
both prokaryotic and eukaryotic oxidoreductases but with
signiﬁcantly different rates. The rate of reduction of MRF by
the bacterial oxidoreductase T4moF (Bailey et al., 2007) was
measured at multiple MRF concentrations in the presence of
saturating NADH. The rate increased linearly with MRF
concentration up to 100 mM, corresponding to an observed
second-order rate of 0.2 mM
1 s
1, and the apparent KM
between T4moF and MRF had a lower limit of 100 mM.I n
comparison, the biological electron-transfer partner for
T4moF, the Rieske-type ferredoxin T4moC, was reduced
at >200 s
1 with an apparent KM of less than 5 mM, giving a
second-order rate constant of >40 mM
1 s
1 (Elsen et al.,
manuscript in preparation).
MRF could also be reduced by the eukaryotic oxido-
reductase ferredoxin NADPH reductase (FdR) from Zea
mays (Ritchie et al., 1994), although at a signiﬁcantly slower
rate (<0.001 mM
1 s
1). Considering the biological electron-
transfer partners of T4moF (T4moC, a Rieske-type ferre-
doxin) and FdR (a plant-type ferredoxin), it is perhaps not
surprising that the bacterial oxidoreductase reduces MRF
more efﬁciently.
T4moF and FdR could also reduce HRF. A second-order
rate constant for reduction by T4moF was not calculated;
however, at 50 mM HRF the reduction rate was similar to that
of MRF and FdR reduced HRF very slowly. After reduction,
exposure to air returned both MRF and HRF to the oxidized
state and gave optical spectra that were identical to those of
the as-isolated proteins. This indicates that the formation of
reactive oxygen species such as superoxide does not damage
the [2Fe–2S] cluster of these ferredoxins.
Despite its capacity to be reduced by T4moF, neither MRF
nor HRF stimulated p-cresol formation when substituted for
T4moC in the T4MO complex. The inability of these Rieske
proteins to transfer electrons to T4moH is either a conse-
quence of a high reduction potential, as suggested by the
hydrogen-bonding pattern, or an inability to form an efﬁcient
electron-transfer complex. Indeed, even BphF, which has a
redox potential similar to that of T4moC and is more closely
related structurally, could not stimulate p-cresol formation,
indicating that a speciﬁc protein–protein interaction between
T4moH and its Rieske-type ferredoxin electron donor is
required for electron transfer (Elsen et al., 2007).
3.8. Possible biological function
The biological electron-transfer partners of Rieske proteins
and Rieske-type ferredoxins include hemes (Link & Iwata,
1996), diiron clusters (Pikus et al., 1996), mononuclear iron
centers ligated by the 2-His-1-carboxylate facial triad (Kauppi
et al., 1998) and [3Fe–4S]/molybdenum cofactors (Ellis et al.,
2001). They are found as membrane-bound subunits (Carrell
et al., 1997), as domains of larger oxidase complexes (Kauppi
et al., 1998), as subunits in the 22 arsenite oxidase (Ellis et al.,
2001) and as soluble monomeric ferredoxins (Moe et al., 2006).
The extended Pro-loop of MRFis most similar to the extended
Pro-loops found in the Rieske domains of the Rieske dioxy-
genases. In NDO, this loop provides an extended interface
with the adjacent subunit and thus helps to stabilize the
trimeric quaternary structure and also orient the [2Fe–2S]
cluster to form an active site that crosses subunit boundaries.
The presence of the extended loop in MRF supports the
likelihood that the protein also undergoes strong and likely
speciﬁc interactions with a presently unknown eukaryotic
electron acceptor. A strong afﬁnity for its electron-transfer
partner may facilitate its identiﬁcation by pull-down methods
using the afﬁnity-tagged MRF.
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(BGF and NLE), National Library of Medicine grant
5T15LM007359 (EJL) and NHGRI training grant
5T32HG002760 (JGM). The authors would like to thank
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